Reduced High-Density Lipoprotein Level is Linked to Worse Ankle Brachial Index and Peak Oxygen Uptake in Postmenopausal Women With Peripheral Arterial Disease
Restricted accessResearch articleFirst published online October, 2010
Reduced High-Density Lipoprotein Level is Linked to Worse Ankle Brachial Index and Peak Oxygen Uptake in Postmenopausal Women With Peripheral Arterial Disease
Women with peripheral arterial disease (PAD) have more limited physical function than men but the mechanisms involved are not clear. We determined whether alterations in lipid components, such as decreased high-density lipoprotein cholesterol (HDL-C), are associated with worsening intermittent claudication (IC) in postmenopausal women with PAD. Our cross-sectional cohort study included 69 postmenopausal women with IC (Fontaine stage II). A treadmill test was used to measure initial claudication distance (ICD), absolute claudication distance (ACD), peak oxygen uptake, and ankle systolic blood pressure. High-density lipoprotein cholesterol correlated with ankle brachial index ([ABI]; R = .29, P = .019). No other lipid profile components were associated with exercise performance and hemodynamic measures. Among women with HDL-C <50 mg/dL (n = 43), the median peak oxygen uptake level was significantly lower (P = .021) relative to women with normal HDL-C >50 mg/dL (n = 26). Lower HDL-C levels are associated with worse ABI and decreased peak oxygen uptake in postmenopausal women with PAD.
Ridker PM, Stampfer MJ, Rifai N.Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA . 2001;285(19): 2481-2485.
3.
McDermott MM , Greenland P., Liu K., et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study . Ann Intern Med. 2002; 136(12):873-883.
4.
McDermott MM, Liu K., Greenland P., et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292(4):453-461.
5.
Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol.2006;47(6):1239-1312.
6.
Aboyans V., Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A.Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113(22): 2623-2629.
7.
Singh IM, Shishehbor MH, Ansell BJHigh-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298(7): 786-798.
8.
Afaq A., Montgomery P., Scott K., Blevins S., Whitsett T., Gardner A.The Effect of Hypercholestrolemia on Calf Muscle Hemoglobin Oxygen Saturation in Patients With Intermittent Claudication. Angiology. 2008;59(5):534-541. Epub 2008 Apr 2.
9.
Brevetti G., Bucur R., Balbarini A., et al. Women and peripheral arterial disease: same disease, different issues. J Cardiovasc Med (Hagerstown). 2008;9(4):382-388.
10.
Collins TC, Suarez-Almazor M., Bush RL, Petersen NJGender and peripheral arterial disease. J Am Board Fam Med.2006; 19(2):132-140.
11.
Gardner AWSex differences in claudication pain in subjects with peripheral arterial disease. Med Sci Sports Exerc. 2002;34(11): 1695-1698.
12.
Garrison RJ , Kannel WB, Feinleib M., Castelli WP, McNamara PM, Padgett SJCigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis. 1978; 30(1):17-25.
13.
Heyden S., Heiss G., Manegold C., et al. The combined effect of smoking and coffee drinking on LDL and HDL cholesterol. Circulation. 1979;60(1):22-25.
14.
Willett W., Hennekens CH, Castelli W., et al. Effects of cigarette smoking on fasting triglyceride, total cholesterol, and HDL-cholesterol in women. Am Heart J. 1983;105(3):417-421.
15.
Gardner AW, Skinner JS, Cantwell BW, Smith LKProgressive vs single-stage treadmill tests for evaluation of claudication . Med Sci Sports Exerc. 1991;23(4):402-408.
16.
Weitz JI, Byrne J., Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94(11):3026-3049.
17.
Mosca L., Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11):1481-1501.
18.
Brunzell JD , Davidson M., Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol.2008;51(15):1512-1524.
19.
McDermott MM , Liu K., Guralnik JM, Martin GJ, Criqui MH, Greenland P.Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg. 1998;28(6):1072-1081.
20.
Gardner AW, Killewich LA, Katzel LI, et al. Relationship between free-living daily physical activity and peripheral circulation in patients with intermittent claudication. Angiology. 1999; 50(4):289-297.
21.
Gardner AW, Skinner JS, Smith LKEffects of handrail support on claudication and hemodynamic responses to single-stage and progressive treadmill protocols in peripheral vascular occlusive disease . Am J Cardiol. 1991;68(1):99-105.
22.
Feinberg RL , Gregory RT, Wheeler JR, et al. The ischemic window: a method for the objective quantitation of the training effect in exercise therapy for intermittent claudication. J Vasc Surg. 1992 ;16(2):244-250.
23.
Gardner AWReliability of transcutaneous oximeter electrode heating power during exercise in patients with intermittent claudication. Angiology. 1997;48(3):229-235.
24.
Komiyama T. , Onozuka A., Miyata T., Shigematsu H.Oxygen saturation measurement of calf muscle during exercise in intermittent claudication. Eur J Vasc Endovasc Surg. 2002;23(5):388-392.
25.
Casavola C. , Paunescu LA, Fantini S., Franceschini MA, Lugara PM, Gratton E.Application of near-infrared tissue oxymetry to the diagnosis of peripheral vascular disease. Clin Hemorheol Microcirc. 1999;21(3-4):389-393.
26.
Comerota AJ , Throm RC, Kelly P., Jaff M.Tissue (muscle) oxygen saturation (StO2): a new measure of symptomatic lower-extremity arterial disease. J Vasc Surg. 2003;38(4):724-729.
27.
Gardner AW, Parker DE, Webb N., Montgomery PS, Scott KJ, Blevins SMCalf muscle hemoglobin oxygen saturation characteristics and exercise performance in patients with intermittent claudication. J Vasc Surg. 2008;48(3):644-649.
28.
Gardner AW, Sieminski DJ, Killewich LAThe effect of cigarette smoking on free-living daily physical activity in older claudication patients. Angiology. 1997 ;48(11):947-955.
29.
Daskalopoulou SS, Pathmarajah M., Kakkos SK, et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J. 2008; 72(3):441-448.
30.
Volpato S., Ble A., Metter EJ, et al. High-density lipoprotein cholesterol and objective measures of lower extremity performance in older nondisabled persons: the InChianti study. J Am Geriatr Soc. 2008;56(4):621-629.
31.
Landi F., Russo A., Cesari M., Pahor M., Bernabei R., Onder G.HDL-cholesterol and physical performance: results from the ageing and longevity study in the sirente geographic area (ilSIRENTE Study). Age Ageing. 2007;36(5):514-520.
32.
Barretto S. , Ballman KV, Rooke TW, Kullo IJEarly-onset peripheral arterial occlusive disease: clinical features and determinants of disease severity and location . Vasc Med. 2003; 8(2):95-100.
33.
Nofer JR, Walter M., Assmann G.Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Rev Cardiovasc Ther. 2005;3(6):1071-1086.
34.
Murphy AJ, Chin-Dusting JP, Sviridov D., Woollard KJThe anti inflammatory effects of high density lipoproteins. Curr Med Chem.2009;16(6):667-675.
35.
Moriarty PM, Gibson CAAssociation between hematological parameters and high-density lipoprotein cholesterol. Curr Opin Cardiol.2005;20(4):318-323.
36.
Miura S., Fujino M., Matsuo Y., et al. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23(5):802-808.
37.
Sumi M., Sata M., Miura S., et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis . Arterioscler Thromb Vasc Biol. 2007;27(4):813-818.
38.
Poussa H., Strandberg TE, Tikkanen I., Kauhanen P., Lepantalo M.Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. Scand Cardiovasc J. 2007;41(3):138-141.
39.
Margeta C., Giurgea A., Hammer A., et al. Impact of international guidelines on the manage-ment of cardiovascular risk factors in diabetic patients with peripheral arterial disease. Int Angiol.2009;28(3):175-180.
40.
McDermott MM , Guralnik JM, Greenland P., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003; 107(5):757-761.
41.
Mohler ER 3rd , Hiatt WR , Creager MACholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481-1486.
42.
Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GCLipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007:CD000123.
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645-654; discussion 653-54.
45.
Briel M., Ferreira-Gonzalez I., You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338:b92.
